US-based pharmaceutical company, Eli Lilly and Company, has announced plans to invest $450m in its manufacturing facilities at Research Triangle Park in North Carolina, US.
Lilly’s expansion is set to include the addition of further parenteral filling, device assembly and packaging capacity in order to meet the growing demand for the company’s incretin-based diabetes treatments and medications. The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel.
